Timing Pharmaceutical Co

Timing Pharmaceutical Co Equity

The The Equity of Timing Pharmaceutical Co (6659.TWO) as of Nov 10, 2026 is 1.06 B TWD. In the previous year, The Equity was 1.02 B TWD — a change of 3.45% (higher).

Equity

1.06 BTWD

YoY

3.45%

Last updated:

In 2024, Timing Pharmaceutical Co's equity was 1.06 B TWD, a 3.45% increase from the 1.02 B TWD equity in the previous year.

The Timing Pharmaceutical Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2022
990.89 M TWD
Jan 1, 2023
1.02 B TWD
Jan 1, 2024
1.06 B TWD
The Timing Pharmaceutical Co Equity history
YEAREquityYoY
1.06 BTWD+3.45%
1.02 BTWD+2.95%
990.89 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Timing Pharmaceutical Co Stock analysis

What does Timing Pharmaceutical Co do? Timing Pharmaceutical Co Ltd generates revenue through manufacturing concentrated Chinese medicine preparations, health foods, and traditional Chinese medicine formulations for domestic and overseas markets. The company accepts applications for licenses and permits related to Chinese medicine, food, and pharmaceutical products, and offers contract manufacturing services. Its comprehensive sales network covers Chinese medicine hospitals and major pharmacies across Taiwan, supported by a professional supply chain and service network. The firm also provides testing services and CDMO services for new pilot projects in research and development. The primary buyers of Timing Pharmaceutical's products include Chinese medicine hospitals, major pharmacies, and overseas markets. Domestic sales are facilitated through a full-fledged professional supply chain and service network, while overseas markets are served through direct exports and partnerships. The company's focus on traditional Chinese medicine and pharmaceuticals drives demand from healthcare institutions and consumers seeking natural health solutions. Timing Pharmaceutical Co Ltd invests annually in research and development for new pilot projects, which are supported by its contract research and development and manufacturing organization (CDMO) services. These services are contracted by clients seeking to develop and manufacture pharmaceutical products, including traditional Chinese medicine formulations. The company's portfolio includes concentrated Chinese medicine preparations, health foods, and traditional Chinese medicine formulations, all of which are distributed through its established network. Timing Pharmaceutical Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Timing Pharmaceutical Co's Equity

Timing Pharmaceutical Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Timing Pharmaceutical Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Timing Pharmaceutical Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Timing Pharmaceutical Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Timing Pharmaceutical Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Timing Pharmaceutical Co stock

The Equity of Timing Pharmaceutical Co is 1.06 B TWD in 2024.

The Equity of Timing Pharmaceutical Co changed from 1.02 B TWD to 1.06 B TWD, representing a 3.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Timing Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Timing Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Timing Pharmaceutical Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Timing Pharmaceutical Co